Glucose News and Research

RSS

Lexicon presents LX4211 Phase 2a clinical trial results for type 2 diabetes mellitus at ENDO 2010

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering breakthrough treatments for human disease, presented clinical data and analysis from its Phase 2a clinical trial of LX4211 for patients with type 2 diabetes mellitus at ENDO 2010 today. The results reported today included newly-obtained data showing a trend of increased total GLP-1 in both LX4211 treatment arms relative to placebo as measured in a post-trial analysis of blood samples.

22 Jun 2010

Gastric bypass surgery improves insulin sensitivity in Type 2 diabetes patients

Gastric bypass surgery improves Type 2 diabetes by other mechanisms in addition to weight loss and does so better than a low-calorie diet despite achieving equal weight loss, a new study finds. The results will be presented Monday at The Endocrine Society's 92nd Annual Meeting in San Diego.

21 Jun 2010

Studies explore effects of fructose consumption on metabolic parameters in humans

New research released today from Rippe Lifestyle Institute and the University of Central Florida shows no difference between table sugar and high fructose corn syrup on weight gain or any changes in risk factors for metabolic syndrome or insulin resistance, a precursor to diabetes. Abstracts for the two studies are the first to provide longer term prospective data exploring the effects the normal consumption of fructose has on metabolic parameters in humans.

21 Jun 2010

Zydus Cadila receives DCGI approval to initiate Phase I clinical trial for ZYOG1

Zydus Cadila, a global healthcare provider and one of India's leading healthcare companies has received Phase I clinical trial permission from the DCGI for ZYOG1 - a novel GLP-1 agonist. Designed and developed at the Zydus Research Centre using a unique platform technology, ZYOG1 is a novel, oral, anti-diabetic molecule.

21 Jun 2010

Special Olympics Minnesota's 2010 Summer Games conclude

Today is the last day of competition at the Special Olympics Minnesota's 2010 Summer Games. Volleyball competition will take place on the third floor of the University of Minnesota's Recreation Center (1906 University Avenue SE) from 9 a.m. to 4 p.m. and tennis competition will be held at Life Time Fitness in Lakeville (18425 Dodd Boulevard) from 9 a.m.-1 p.m. In addition, artistic gymnastics competition will start at 2 p.m. and conclude at 5:30 p.m. at Mini-Hops Gymnastics Club in Minnetonka (131 Cheshire Lane, Suite 100).

19 Jun 2010

Ancient circadian clock regulates insulin production

The pancreas has its own molecular clock. Now, for the first time, a Northwestern University study has shown this ancient circadian clock regulates the production of insulin. If the clock is faulty, the result is diabetes.

19 Jun 2010

Physical fitness reduces metabolic risk in college students

Staying in shape may bolster the metabolic profiles of college students, even in those with higher than desirable body fat percentages. In an epidemiological study, researchers at the Friedman School of Nutrition Science and Policy at Tufts University found an association between physical fitness, body fat percentage and certain metabolic risk factors that are precursors to cardiovascular disease and Type 2 diabetes.

18 Jun 2010

Data on BYETTA and SYMLIN injections, BYDUREON drug candidate to be presented at ADA 2010

Amylin Pharmaceuticals, Inc. today announced that the Company will present data for its FDA-approved diabetes drugs, BYETTA (exenatide) injection and SYMLIN (pramlintide acetate) injection, and its investigational diabetes drug candidate BYDUREON (exenatide extended-release for injectable suspension) at the American Diabetes Association's 70th Annual Scientific Sessions being held in Orlando, FL from June 25 to June 29.

18 Jun 2010

DURATION-4 study tests superiority of BYDUREON as compared to other type 2 diabetes medications

Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced results from DURATION-4, the fourth in a series of studies designed to test the superiority of BYDUREON (exenatide extended-release for injectable suspension), an investigational type 2 diabetes therapy, as compared to other type 2 diabetes medications.

18 Jun 2010

Research identifies early biomarker for insulin resistance, glucose intolerance in nondiabetic population

Metabolon, Inc., the leader in metabolomics-based biomarker discovery and analysis, today announced the publication of research that identified a novel, early biomarker for insulin resistance and glucose intolerance in a nondiabetic population.

17 Jun 2010

Deuterium depletion symposium focusses on oncotherapy, anticancer, diabetes, anti-aging research

1st International Symposium on Deuterium Depletion was held on 13-14 May 2010 in Budapest, Hungary. The conference programme focused on the advances in the research and clinical application of deuterium depletion, its present and future role in anticancer research and oncotherapy, diabetes research and anti-aging.

17 Jun 2010

Management of cardiovascular risk associated with insulin resistance, diabetes, and the metabolic syndrome

Adi Mehta, MD stresses the growing severity of the metabolic syndrome in the May 2010 edition of Postgraduate Medicine. Metabolic syndrome often leads to cardiovascular disease (CVD) because of its key components: diabetes, dyslipidemia, and hypertension. With obesity maintaining its status as a huge problem worldwide, physicians must act as soon as possible when they recognize metabolic syndrome or any of its components.

16 Jun 2010

New perspectives in type 2 diabetes, cardiovascular risk, and treatment goals

An article published in the May 2010 issue of Postgraduate Medicine highlights the seriousness of cardiovascular disease (CVD) in patients with type 2 diabetes. Cardiovascular disease is the cause of death in > 65% of patients with diabetes, and when complicated by the presence of obesity, the lifetime risk of developing CVD increases to 90%. The inherent problem is that many of the antihyperglycemic medications used to combat high glycated hemoglobin are associated with weight gain and/or hypoglycemia, which negatively affect CVD.

16 Jun 2010

European market for continuous glucose monitoring to reach $52M in 2016

The continuous glucose monitoring (CGM) market is in its development stage. The primary factor leading to the growth of the (CGM) market in Europe is the need for an easy-to-use and patient-friendly glucose-monitoring device. The traditional method of monitoring glucose was difficult and inconvenient for patients. The CGM method is not only hassle-free, but also gives a better diagnosis of diabetes.

16 Jun 2010

Hormone that helps regulate blood sugar levels may influence sensitivity to sweet-tasting foods: Study

A hormone that helps to regulate blood sugar levels may also influence a person's sensitivity to sweet-tasting foods, according to a new study from researchers at the University of Maryland School of Medicine. They found that blocking the tongue's ability to respond to the hormone known as glucagon decreases the taste system's sensitivity to sweetness.

16 Jun 2010

New analysis contradicts study that brain consumes extra glucose when people exert self-control

Contradicting a popular model of self-control, a University of Pennsylvania psychologist says the data from a 2007 study argues against the idea that glucose is the resource used to manage self control and that humans rely on this energy source for will power.

14 Jun 2010

CinGx safe and effective for treating diabetes, Alzheimer’s and dementia

There is currently no cure for Diabetes, Alzheimer's and Dementia but they can be treated and prevented. Allegiance Equity developed CinGx™ as a safe and effective treatment for these diseases.

11 Jun 2010

Type 2 diabetes doubles risk of cancer in women

Type 2 adult-onset diabetes causes insulin-like hormones to circulate through the body. A new study finds this has a surprisingly positive effect on reducing the rate of prostate cancer in men, but is bad news for women: Type 2 diabetes may double the risk of female genital and other cancers.

11 Jun 2010

AFREZZA non-inferior to standard therapy insulin lispro in reducing HbA1c levels of Type 1 diabetics

MannKind Corporation today announced that results of a new 16-week trial show that the investigational ultra rapid acting mealtime insulin, AFREZZA™ (insulin human [rDNA origin]) Inhalation Powder, combined with basal insulin, is clearly non-inferior to standard therapy insulin lispro, a rapid acting insulin, also combined with basal insulin, in reducing HbA1c levels in subjects with inadequately controlled Type 1 diabetes.

11 Jun 2010

PHT, Entra Health partner to provide integrated data monitoring technology for clinical trials in diabetes

PHT Corporation, the leading provider of electronic patient reported outcome (ePRO) solutions today announced a strategic partnership with Entra Health Systems, an international applied healthcare technology company. Together PHT and Entra Health will provide integrated data monitoring technology for the management of clinical trials for the treatment of diabetes and in trials where blood glucose management plays a critical role in the investigation.

10 Jun 2010

Glucose News and Research

Lexicon presents LX4211 Phase 2a clinical trial results for type 2 diabetes mellitus at ENDO 2010

Gastric bypass surgery improves insulin sensitivity in Type 2 diabetes patients

Studies explore effects of fructose consumption on metabolic parameters in humans

Zydus Cadila receives DCGI approval to initiate Phase I clinical trial for ZYOG1

Special Olympics Minnesota's 2010 Summer Games conclude

Ancient circadian clock regulates insulin production

Physical fitness reduces metabolic risk in college students

Data on BYETTA and SYMLIN injections, BYDUREON drug candidate to be presented at ADA 2010

DURATION-4 study tests superiority of BYDUREON as compared to other type 2 diabetes medications

Research identifies early biomarker for insulin resistance, glucose intolerance in nondiabetic population

Deuterium depletion symposium focusses on oncotherapy, anticancer, diabetes, anti-aging research

Management of cardiovascular risk associated with insulin resistance, diabetes, and the metabolic syndrome

New perspectives in type 2 diabetes, cardiovascular risk, and treatment goals

European market for continuous glucose monitoring to reach $52M in 2016

Hormone that helps regulate blood sugar levels may influence sensitivity to sweet-tasting foods: Study

New analysis contradicts study that brain consumes extra glucose when people exert self-control

CinGx safe and effective for treating diabetes, Alzheimer’s and dementia

Type 2 diabetes doubles risk of cancer in women

AFREZZA non-inferior to standard therapy insulin lispro in reducing HbA1c levels of Type 1 diabetics

PHT, Entra Health partner to provide integrated data monitoring technology for clinical trials in diabetes

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News